Magazine Article | March 1, 2019

The Unique Demands of Cell and Gene Therapy Supply Chains

Source: Life Science Leader

By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1

Innovations in the cell and gene sector continue to advance development of safe and effective therapies. But can the cell and gene therapy sector’s exceptionally complex supply chains keep up with the rapid rate of progress? I conferred with three of the field’s most valuable luminaries representing both academia and industry — Dr. Bruce Levine, Barbara and Edward Netter professor in Cancer Gene Therapy at the University of Pennsylvania; Simon Ellison, ISCT (International Society of Cell & Gene Therapy) Commercialization Committee; and Ryan Bartock, head of supply chain and network strategy at Spark Therapeutics — to determine how CMOs can and should successfully manage cell and gene therapy supply chains.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: